ICAD
Price
$3.22
Change
+$0.15 (+4.89%)
Updated
Apr 17 closing price
Capitalization
42.43M
30 days until earnings call
NEO
Price
$9.55
Change
-$0.01 (-0.10%)
Updated
Apr 17 closing price
Capitalization
2.01B
10 days until earnings call
Ad is loading...

ICAD vs NEO

Header iconICAD vs NEO Comparison
Open Charts ICAD vs NEOBanner chart's image
iCAD
Price$3.22
Change+$0.15 (+4.89%)
Volume$2.02M
Capitalization42.43M
NeoGenomics
Price$9.55
Change-$0.01 (-0.10%)
Volume$1.36M
Capitalization2.01B
ICAD vs NEO Comparison Chart
Loading...
ICAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ICAD vs. NEO commentary
Apr 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ICAD is a StrongBuy and NEO is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 19, 2025
Stock price -- (ICAD: $3.22 vs. NEO: $9.55)
Brand notoriety: ICAD and NEO are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: ICAD: 241% vs. NEO: 83%
Market capitalization -- ICAD: $42.43M vs. NEO: $2.01B
ICAD [@Medical Specialties] is valued at $42.43M. NEO’s [@Medical Specialties] market capitalization is $2.01B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ICAD’s FA Score shows that 0 FA rating(s) are green whileNEO’s FA Score has 0 green FA rating(s).

  • ICAD’s FA Score: 0 green, 5 red.
  • NEO’s FA Score: 0 green, 5 red.
According to our system of comparison, ICAD is a better buy in the long-term than NEO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ICAD’s TA Score shows that 4 TA indicator(s) are bullish while NEO’s TA Score has 5 bullish TA indicator(s).

  • ICAD’s TA Score: 4 bullish, 5 bearish.
  • NEO’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, NEO is a better buy in the short-term than ICAD.

Price Growth

ICAD (@Medical Specialties) experienced а +92.81% price change this week, while NEO (@Medical Specialties) price change was +7.30% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.65%. For the same industry, the average monthly price growth was -9.67%, and the average quarterly price growth was -5.07%.

Reported Earning Dates

ICAD is expected to report earnings on Aug 06, 2025.

NEO is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Medical Specialties (+1.65% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NEO($2.01B) has a higher market cap than ICAD($42.4M). ICAD YTD gains are higher at: 75.956 vs. NEO (-42.051). ICAD has higher annual earnings (EBITDA): -12.18M vs. NEO (-17.61M). NEO has more cash in the bank: 415M vs. ICAD (19M). ICAD has less debt than NEO: ICAD (514K) vs NEO (612M). NEO has higher revenues than ICAD: NEO (592M) vs ICAD (25.4M).
ICADNEOICAD / NEO
Capitalization42.4M2.01B2%
EBITDA-12.18M-17.61M69%
Gain YTD75.956-42.051-181%
P/E RatioN/A49.50-
Revenue25.4M592M4%
Total Cash19M415M5%
Total Debt514K612M0%
FUNDAMENTALS RATINGS
ICAD vs NEO: Fundamental Ratings
ICAD
NEO
OUTLOOK RATING
1..100
9118
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9292
PRICE GROWTH RATING
1..100
5682
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ICAD's Valuation (40) in the Computer Peripherals industry is somewhat better than the same rating for NEO (73) in the Medical Or Nursing Services industry. This means that ICAD’s stock grew somewhat faster than NEO’s over the last 12 months.

ICAD's Profit vs Risk Rating (100) in the Computer Peripherals industry is in the same range as NEO (100) in the Medical Or Nursing Services industry. This means that ICAD’s stock grew similarly to NEO’s over the last 12 months.

ICAD's SMR Rating (92) in the Computer Peripherals industry is in the same range as NEO (92) in the Medical Or Nursing Services industry. This means that ICAD’s stock grew similarly to NEO’s over the last 12 months.

ICAD's Price Growth Rating (56) in the Computer Peripherals industry is in the same range as NEO (82) in the Medical Or Nursing Services industry. This means that ICAD’s stock grew similarly to NEO’s over the last 12 months.

ICAD's P/E Growth Rating (100) in the Computer Peripherals industry is in the same range as NEO (100) in the Medical Or Nursing Services industry. This means that ICAD’s stock grew similarly to NEO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ICADNEO
RSI
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
76%
Momentum
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
69%
MACD
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
69%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
80%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 5 days ago
77%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 18 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
80%
Aroon
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
79%
View a ticker or compare two or three
Ad is loading...
ICAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME26.780.53
+2.02%
GameStop Corp
AAPL196.982.71
+1.39%
Apple
BTC.X84895.750000861.882800
+1.03%
Bitcoin cryptocurrency
SPY526.410.75
+0.14%
SPDR® S&P 500® ETF
TSLA241.37-0.18
-0.07%
Tesla

ICAD and

Correlation & Price change

A.I.dvisor tells us that ICAD and KRMD have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ICAD and KRMD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ICAD
1D Price
Change %
ICAD100%
+4.89%
KRMD - ICAD
31%
Poorly correlated
-0.87%
HYPR - ICAD
29%
Poorly correlated
+4.11%
BLFS - ICAD
28%
Poorly correlated
-1.57%
AVNS - ICAD
28%
Poorly correlated
+3.07%
NEO - ICAD
28%
Poorly correlated
-0.10%
More

NEO and

Correlation & Price change

A.I.dvisor indicates that over the last year, NEO has been loosely correlated with FLGT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if NEO jumps, then FLGT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NEO
1D Price
Change %
NEO100%
-0.10%
FLGT - NEO
45%
Loosely correlated
-2.51%
RGEN - NEO
45%
Loosely correlated
-1.59%
VCYT - NEO
43%
Loosely correlated
-1.24%
BLFS - NEO
43%
Loosely correlated
-1.57%
CSTL - NEO
42%
Loosely correlated
+1.18%
More